Huihui Chi

Huihui Chi

Auto-generated profile, based on publicly available information

Huihui Chi

Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, China

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 January 2019 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
QHQiongyi Hu
Qiongyi Hu
HSHui Shi
Hui Shi
TZTing Zeng
Ting Zeng
HLHong-Lei Liu
Hong-Lei Liu
YSYutong Su
Yutong Su
CYChengde Yang
Chengde Yang
Adult-onset Still’s disease (AOSD) is a systemic inflammatory disease characterized by neutrophilia and NLRP3 inflammasome and macrophage activation. We investigated the role of neutrophil extracellular traps (NETs) in the pathogenesis of AOSD, and explored the effect of NETs on activating NLRP3 inflammasome and proinflammatory macrophages. The sera of 73 AOSD patients and 40 healthy controls were used to detect the level of cell-free DNA and NET-DNA complexes. NET formation ex vivo was analyzed using immunofluorescence and flow plates. The activation of NLRP3 inflammasome in THP-1 cells and proinflammatory macrophages stimulated with DNA purified from NETs was measured using RT-PCR, ELISA, Western blotting and flow cytometry. The levels of cell-free DNA and NET-DNA complexes were significantly increased in the circulation of patients with AOSD compared with healthy controls, and freshly isolated neutrophils from patients with AOSD were predisposed to high levels of spontaneous NET release. Interestingly, enhanced NET release was abrogated with NADPH oxidase inhibitors and a mitochondrial scavenger. Furthermore, DNA purified from AOSD NETs activated NLRP3 inflammasomes. NET DNA from AOSD also exerted a potent capacity to accelerate the activation of CD68+CD86+ macrophages and increased the expression of interleukin (IL)-1β, IL-6, and tumor necrosis factor (TNF)-α. Finally, the copy number of mitochondrial DNA (mtDNA) in NETs and plasma was significantly increased in AOSD patients, suggesting that mtDNA may be involved in the activation of NLRP3 and inflammatory macrophages. These findings implicate accelerated NET formation in AOSD pathogenesis through activation of NLRP3 and proinflammatory macrophages, and identify a novel link between neutrophils and macrophages by NET formation in AOSD.

10 November 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
JJJinchao Jia
Jinchao Jia
MWMengyan Wang
Mengyan Wang
JMJianfen Meng
Jianfen Meng
YMYuning Ma
Yuning Ma
YWYang Wang
Yang Wang
QHQiongyi Hu
Qiongyi Hu
Hyperferritinemic syndrome, an overwhelming inflammatory condition, is characterized by high ferritin levels, systemic inflammation and multi-organ dysfunction, but the pathogenic role of ferritin remains largely unknown. Here we show in an animal model that ferritin administration leads to systemic and hepatic inflammation characterized by excessive neutrophil leukocyte infiltration and neutrophil extracellular trap (NET) formation in the liver tissue. Ferritin-induced NET formation depends on the expression of peptidylarginine deiminase 4 and neutrophil elastase and on reactive oxygen species production. Mechanistically, ferritin exposure increases both overall and cell surface expression of Msr1 on neutrophil leukocytes, and also acts as ligand to Msr1 to trigger the NET formation pathway. Depletion of neutrophil leukocytes or ablation of Msr1 protect mice from tissue damage and the hyperinflammatory response, which further confirms the role of Msr1 as ferritin receptor. The relevance of the animal model is underscored by the observation that enhanced NET formation, increased Msr1 expression and signalling on neutrophil leukocytes are also characteristic to adult-onset Still’s disease (AOSD), a typical hyperferritinemic syndrome. Collectively, our findings demonstrate an essential role of ferritin in NET-mediated cytokine storm, and suggest that targeting NETs or Msr1 may benefit AOSD patients.

1 June 2020 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
QHQiongyi Hu
Qiongyi Hu
MWMengyan Wang
Mengyan Wang
JJJinchao Jia
Jinchao Jia
JTJialin Teng
Jialin Teng
HCHuihui Chi
Huihui Chi
CYChengde Yang
Chengde Yang
Table 1 Baseline information of the AOSD patients at enrolment No. G Age Disease duration (months) Clinical manifestations Previous treatments Treatments before JAKi initiation Treatments after enrolment Follow-up (months) Clinical evaluation CR time with JAKi (months) Present pred dose (mg/day) 1 F 33 12 Polyarthritis, rash CTX, MTX, CsA, NSAIDs iguratimod, thalidomide, Pred 40 mg+tocilizumab Pred 40 mg+JAKi 5 mg two times per day 24 Effective 16 2.5

22 March 2018 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
HCHuihui Chi
Huihui Chi
DLDongzhou Liu
Dongzhou Liu
YSYue Sun
Yue Sun
QHQiongyi Hu
Qiongyi Hu
HLHonglei Liu
Honglei Liu
YSYutong Su
Yutong Su
Interleukin (IL)-37 has been known to play an immunosuppressive role in various inflammatory disorders, but whether it participates in the regulation of pathogenesis of adult-onset Still’s disease (AOSD) has not been investigated. In this study, we examined serum IL-37 levels and their clinical association with AOSD, and we explored the anti-inflammatory effects of IL-37 on peripheral blood mononuclear cells (PBMCs) from patients with AOSD. Blood samples were collected from 62 patients with AOSD and 50 healthy control subjects (HC). The serum IL-37 levels were determined using an enzyme-linked immunosorbent assay (ELISA). The correlations of serum IL-37 levels with disease activity, laboratory values, and inflammatory cytokines in AOSD were analyzed by Spearman’s correlation test. The correlations between serum IL-37 levels and clinical manifestations were analyzed by Mann-Whitney U test. PBMCs from ten patients with AOSD were stimulated with recombinant human IL-37 protein, and expression levels of tumor necrosis factor (TNF)-α, IL-6, IL-10, IL-1β, and IL-18 were determined by qRT-PCR and ELISA. A significantly higher IL-37 protein level was observed in patients with AOSD than in HC. Serum IL-37 levels correlated with systemic score, laboratory values, IL-1β, IL-18, and IL-10 in patients with AOSD. The expression levels of IL-37 were closely related to the patients with AOSD who also had fever, skin rash, lymphadenopathy, splenomegaly, myalgia, and arthralgia. Moreover, the production of proinflammatory cytokines such as IL-6, IL-1β, TNF-α, and IL-18 in PBMCs from patients with AOSD was obviously attenuated after recombinant human IL-37 stimulation. Increased expression of IL-37 and its positive correlation with disease activity suggest its involvement in AOSD pathogenesis. More importantly, IL-37 inhibits the expression of proinflammatory cytokines in PBMCs from patients with AOSD, indicating the potential anti-inflammatory role of IL-37 in AOSD. Thus, IL-37 may be a novel disease activity biomarker and research target in AOSD.

21 August 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
ZTZihan Tang
Zihan Tang
YXYanyan Xu
Yanyan Xu
YTYun Tan
Yun Tan
HSHui Shi
Hui Shi
PJPeipei Jin
Peipei Jin
TLTingting Liu
Tingting Liu
Aberrant coagulation and thrombosis are associated with severe COVID-19 post-SARS-CoV-2 infection, yet the underlying mechanism remains obscure. Here we show that serum levels of SARS-CoV-2 envelope (E) protein are associated with coagulation disorders of COVID-19 patients, and intravenous administration of the E protein is able to potentiate thrombosis in mice. Through protein pull-down and mass spectrometry, we find that CD36, a transmembrane glycoprotein, directly binds with E protein and mediates hyperactivation of human and mouse platelets through the p38 MAPK-NF-κB signaling pathway. Conversely, the pharmacological blockade of CD36 or p38 notably attenuates human platelet activation induced by the E protein. Similarly, the genetic deficiency of CD36, as well as the pharmacological inhibition of p38 in mice, significantly diminishes E protein-induced platelet activation and thrombotic events. Together, our study reveals a critical role for the CD36-p38 axis in E protein-induced platelet hyperactivity, which could serve as an actionable target for developing therapies against aberrant thrombotic events related to the severity and mortality of COVID-19.

1 January 2020 in Thrombosis Research
Verified
Journal Article
Closed access
TLTingting Liu
Tingting Liu
JGJieyu Gu
Jieyu Gu
LWLiyan Wan
Liyan Wan
QHQiongyi Hu
Qiongyi Hu
JTJialin Teng
Jialin Teng
HSHui Shi
Hui Shi